Loading this company
Penumbra, Inc.
PENPrices in USD
TickerWorth ScoreD41/100
What we think
Priced above our range of $52.39 to $107.37.
Price
$321.57USD up +$0.71 (+0.22%)
Quoted · Prices are delayed.
Showing the last price we hold for this listing, recorded 2026-10-19 15:48 UTC (8 hours ago).
Why did it move today?
Nothing we can cite explains today’s move for this company.
Is it cheap?
Our range from 2 models, on today’s numbers
$52.39–$107.37
What the price needs: revenue growth of more than 25%/yr for 5 years (our model assumes 10.1%), or investors accepting a ~3.4% discount rate, vs the 8.6% our model uses.
Led by peer multiples (P/E, EV/EBITDA, P/S) · Fast grower
Price $321.57Priced · Prices are delayed.
Is it a good business?
- Valuation0 out of 100
- Growth67 out of 100
- Financial health100 out of 100
- Past performance83 out of 100
Bull, base, bear
Our forward range over 12 months is part of Pro. See plans
The street
Analysts’ mean target
$362.54 across 13 analysts
The high and low of the analyst range is part of Pro. See plans
What does it do?
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It operates in the Medical Devices industry (Healthcare sector), headquartered in United States. The company employs roughly 4,700 people.
Revenue: Thrombectomy 68% · Embolization and Other 32%
Key stats
52-week range$221.26–$362.41
- Open
- $320.30
- Day high
- $321.69
- Day low
- $320.52
- Previous close
- $320.86
- Volume
- 39,961 · 0.12× avg
- Average volume
- 338,528
- Market cap
- $12,666,457,088.00
- P/E (TTM)
- 79.01
- Earnings per share
- $4.07
- Beta
- 0.70
Prices are delayed. The feed does not say when these figures were taken.
What’s the latest?
- Reported quarterly or annual results
- Reported shareholder vote results
- Reported shareholder vote results
- Reported quarterly or annual results
- Reported quarterly or annual results
- Signed a material agreement
- Reported quarterly or annual results
Top news
No recent headlines we can cite for this company.
Insider trades
The 90-day buying-and-selling read is part of Pro. See plans
- Narayan ShruthiShares withheld (tax) · $439,080.40
- Narayan ShruthiShares withheld (tax) ·
Not investment advice. TickerWorth Score is a model output.